OBJECTIVES: Both ketamine and ethanol are N-methyl-d-aspartate (NMDA) receptor antagonists. Ketamine has rapid antidepressant properties in major depressive disorder (MDD) as well as bipolar depression. In individuals with MDD, a positive family history of alcohol dependence (FHP) was associated with greater improvement in depressive symptoms after ketamine administration compared to individuals whose family history of alcohol dependence was negative (FHN). This study investigated whether FHP influences ketamine's antidepressant and perceptual effects in individuals with bipolar depression. METHODS: A post hoc analysis was conducted on 33 subjects with DSM-IV bipolar disorder (BD) type I or II depression pooled from two previously published studies. All subjects had undergone a double-blind, randomized, crossover trial of a single intravenous infusion of ketamine (0.5 mg/kg) combined with lithium or valproate therapy. Subjects were rated at baseline; at 40, 80, 120, and 230 min; and at days 1, 2, 3, 7, 10, and 14 post-infusion. The primary outcome measure was Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Patients were categorized as FHP when they reported at least one first-degree relative with alcohol dependence. Measures of psychosis, dissociation, and dysphoria were also collected. RESULTS: After ketamine infusion, subjects with FHP showed significantly greater improvement on MADRS scores than FHN subjects. In addition, patients with FHP had attenuated psychotomimetic and dissociative scores compared to FHN patients. CONCLUSIONS:FHP appears to predict a more sustained antidepressant response to ketamine in individuals with BD. Family history of alcoholism may be an important consideration in the development of glutamatergic-based therapies for depression. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
RCT Entities:
OBJECTIVES: Both ketamine and ethanol are N-methyl-d-aspartate (NMDA) receptor antagonists. Ketamine has rapid antidepressant properties in major depressive disorder (MDD) as well as bipolar depression. In individuals with MDD, a positive family history of alcohol dependence (FHP) was associated with greater improvement in depressive symptoms after ketamine administration compared to individuals whose family history of alcohol dependence was negative (FHN). This study investigated whether FHP influences ketamine's antidepressant and perceptual effects in individuals with bipolar depression. METHODS: A post hoc analysis was conducted on 33 subjects with DSM-IV bipolar disorder (BD) type I or II depression pooled from two previously published studies. All subjects had undergone a double-blind, randomized, crossover trial of a single intravenous infusion of ketamine (0.5 mg/kg) combined with lithium or valproate therapy. Subjects were rated at baseline; at 40, 80, 120, and 230 min; and at days 1, 2, 3, 7, 10, and 14 post-infusion. The primary outcome measure was Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Patients were categorized as FHP when they reported at least one first-degree relative with alcohol dependence. Measures of psychosis, dissociation, and dysphoria were also collected. RESULTS: After ketamine infusion, subjects with FHP showed significantly greater improvement on MADRS scores than FHN subjects. In addition, patients with FHP had attenuated psychotomimetic and dissociative scores compared to FHNpatients. CONCLUSIONS: FHP appears to predict a more sustained antidepressant response to ketamine in individuals with BD. Family history of alcoholism may be an important consideration in the development of glutamatergic-based therapies for depression. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Nancy Diazgranados; Lobna Ibrahim; Nancy E Brutsche; Andrew Newberg; Phillip Kronstein; Sami Khalife; William A Kammerer; Zenaide Quezado; David A Luckenbaugh; Giacomo Salvadore; Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate Journal: Arch Gen Psychiatry Date: 2010-08
Authors: Carlos A Zarate; Jorge A Quiroz; Jaskaran B Singh; Kirk D Denicoff; Georgette De Jesus; David A Luckenbaugh; Dennis S Charney; Husseini K Manji Journal: Biol Psychiatry Date: 2005-02-15 Impact factor: 13.382
Authors: Michael J Ostacher; Roy H Perlis; Andrew A Nierenberg; Joseph Calabrese; Jonathan P Stange; Ihsan Salloum; Roger D Weiss; Gary S Sachs Journal: Am J Psychiatry Date: 2009-12-15 Impact factor: 18.112
Authors: Laura E Phelps; Nancy Brutsche; Jazmin R Moral; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate Journal: Biol Psychiatry Date: 2008-11-08 Impact factor: 13.382
Authors: Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür Journal: Neuropsychopharmacology Date: 2009-12-02 Impact factor: 7.853
Authors: Fabiano G Nery; Jeffrey A Stanley; Hua-Hsuan Chen; John P Hatch; Mark A Nicoletti; E Serap Monkul; Beny Lafer; Jair C Soares Journal: J Psychiatr Res Date: 2009-10-08 Impact factor: 4.791
Authors: Gunter Schumann; Monika Johann; Josef Frank; Ulrich Preuss; Norbert Dahmen; Manfred Laucht; Marcella Rietschel; Dan Rujescu; Anbarasu Lourdusamy; Toni-Kim Clarke; Kristina Krause; Anne Dyer; Martin Depner; Stefan Wellek; Jens Treutlein; Armin Szegedi; Ina Giegling; Sven Cichon; Dorothea Blomeyer; Andreas Heinz; Simon Heath; Mark Lathrop; Norbert Wodarz; Michael Soyka; Rainer Spanagel; Karl Mann Journal: Arch Gen Psychiatry Date: 2008-07
Authors: Raymond F Anton; Gabor Oroszi; Stephanie O'Malley; David Couper; Robert Swift; Helen Pettinati; David Goldman Journal: Arch Gen Psychiatry Date: 2008-02
Authors: James W Murrough; Le-Ben Wan; Brian Iacoviello; Katherine A Collins; Carly Solon; Benjamin Glicksberg; Andrew M Perez; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu; Katherine E Burdick Journal: Psychopharmacology (Berl) Date: 2013-09-11 Impact factor: 4.530
Authors: Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney Journal: Annu Rev Pharmacol Toxicol Date: 2014 Impact factor: 13.820
Authors: Mark J Niciu; Daniel C Mathews; Allison C Nugent; Dawn F Ionescu; Maura L Furey; Erica M Richards; Rodrigo Machado-Vieira; Carlos A Zarate Journal: Depress Anxiety Date: 2013-12-18 Impact factor: 6.505
Authors: Ashley A Conley; Amber E Q Norwood; Thomas C Hatvany; James D Griffith; Kathryn E Barber Journal: Psychopharmacology (Berl) Date: 2021-03-31 Impact factor: 4.530
Authors: Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Sara Guevara; Rodrigo Machado-Vieira; Erica M Richards; Nancy E Brutsche; Neal M Nolan; Carlos A Zarate Journal: J Clin Psychiatry Date: 2014-05 Impact factor: 4.384